Revenue grew 12%
to $174M. Now
three products are
selling, not one.
Optune Gio for brain cancer; Optune Lua for lung cancer; Optune Pax — newly launched — for pancreatic cancer.
↓ scroll to read
✦ The bottom line
Q1 2026 revenue of $174 million was up 12% YoY. The biggest contribution still comes from Optune Gio (glioblastoma brain cancer, 4,543 active patients), but Optune Lua (lung cancer) is up 56% in active patients YoY, and the new Optune Pax (pancreatic cancer) just launched after FDA approval in February.
↓ the brief below
✦ Teach me
What 'Tumor Treating Fields' actually do
TTFields isn't a drug. It's low-intensity alternating electric fields — delivered to the tumor through transducer arrays (essentially patches) the patient wears most of the day. Inside dividing cancer cells, the electric field disrupts the proteins that organize cell division, killing the cell or stopping it from replicating. Each approved product has different patch geometry and electrical settings tuned for the tumor location.
Wall Street calls this
Bio-electric oncology
Because it's a *device* not a drug, the revenue model is more like medical equipment — recurring patch sales, fewer patent-cliff risks, but higher dependence on insurance reimbursement.
The top line · latest quarter
$174
M
Q1 2026 revenue of $174M, up 12% YoY — driven by active-patient growth in European markets and the first contribution from Optune Pax in the U.S.
What revenue should tell you is where the growth is coming from. NovoCure's mix is shifting from a single-product story to a three-product franchise — slowly, but visibly.
The commitment · FY2026 guidance
$690-710
M
Management raised FY2026 guidance to $690-710M (from $675-705M). New products (Optune Lua + Optune Pax) expected to contribute $15-25M combined.